Virological response to adefovir monotherapy and the risk of adefovir resistance

Table 4 Incidence of ADV resistance according to HBV DNA levels

HBV DNA level	Patient number	ADV resistance at week 48 n (%)	ADV resistance at week 96 n (%)
Week 12a
< 60 IU/mL	18	2 (11)	2 (11)
≥ 60 to < 2000 IU/mL	21	0 (0)	0 (0)
> 2000 IU/mL	38	6 (16)	12 (32)
Week 24b
< 60 IU/mL	26	2 (8)	2 (8)
≥ 60 to < 2000 IU/mL	19	1 (5)	1 (5)
> 2000 IU/mL	32	5 (16)	11 (34)
Week 48c
< 60 IU/mL	34	2 (6)	2 (6)
≥ 60 to < 2000 IU/mL	16	0 (0)	3 (19)
> 2000 IU/mL	27	6 (22)	9 (33)

^aP value; week 48 = 0.162, week 96 = 0.007.

^bP value; week 48 = 0.431, week 96 = 0.008.

^cP value; week 48 = 0.036, week 96 = 0.022. ADV: Adefovir dipivoxil; HBV: Hepatitis B virus.